BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination with tislelizumab, BeiGene's antibody targeting PD-1.

BioAtla LLC (San Diego, Calif.) will receive $20 million up front and is eligible for undisclosed early clinical milestones, plus $249 million in subsequent milestones. BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) will receive a co-exclusive license with BioAtla for development and manufacturing of the candidate, and an exclusive, worldwide license to commercialize it globally...